OvaScience, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
OvaScience, Inc. - overview
Established
2011
Location
Waltham, MA, US
Primary Industry
Biotechnology
About
OvaScience, Inc. focuses on advancing reproductive health by developing innovative treatments for infertility, emphasizing the utilization of advanced cellular technologies to improve outcomes for prospective parents. OvaScience, Inc. was founded in 2011 and is based in Waltham, US.
The company specializes in creating solutions for infertility, employing advanced cellular therapies. OvaScience has undergone significant funding initiatives, including a Private Placement/Follow on round where it raised USD 53. 80 mn in May 2016, and previously raised USD 132. 30 mn in January 2015.
Notably, a reverse merger with Millendo Therapeutics, Inc. was completed in December 2018, allowing OvaScience to operate under the Millendo name. The company has been involved in a total of 9 funding deals with the most recent deal occurring on March 4, 2014. OvaScience, Inc.
develops innovative fertility treatments that leverage advanced cellular technologies to enhance reproductive health. Their proprietary platform aims to increase the chances of conception and improve the outcomes of assisted reproductive techniques, specifically targeting women facing infertility issues. The company focuses on research and development to provide effective solutions tailored to the needs of patients seeking support in their reproductive journeys. In the most recent financial year of 2017, OvaScience reported a revenue of USD 295,000.
The company's EBITDA for the same year stood at USD -48,897,000, reflecting significant operational challenges faced during that period. Looking ahead, OvaScience, Inc. aims to expand its product offerings and enhance its existing fertility treatments. The company plans to invest in the development of new therapies to improve success rates for patients undergoing fertility treatments.
Recent funding will be directed towards R&D initiatives and exploring potential market expansion in North America and Europe by the end of 2023. The funds raised through the successful Private Placement/Follow on round will support these strategic objectives, allowing OvaScience to solidify its presence in the reproductive health sector.
Current Investors
Bessemer Venture Partners, Longwood Fund, General Catalyst Partners
Primary Industry
Biotechnology
Sub Industries
Bioinformatics
Website
www.ovascience.com
Company Stage
PIPE
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.